US 11,931,352 B2
Combination therapies for treating cancer
John H. Bushweller, Crozet, VA (US); Anuradha Illendula, Crozet, VA (US); Lucio Hernan Castilla, Boston, MA (US); and John Anto Pulikkan, Boston, MA (US)
Assigned to UNIVERSITY OF VIRGINIA PATENT FOUNDATION, Charlottesville, VA (US); and UNIVERSITY OF MASSACHUSETTS, Boston, MA (US)
Appl. No. 17/056,459
Filed by UNIVERSITY OF VIRGINIA PATENT FOUNDATION, Charlottesville, VA (US); and UNIVERSITY OF MASSACHUSETTS, Boston, MA (US)
PCT Filed May 24, 2019, PCT No. PCT/US2019/033889
§ 371(c)(1), (2) Date Nov. 18, 2020,
PCT Pub. No. WO2019/226975, PCT Pub. Date Nov. 28, 2019.
Claims priority of provisional application 62/676,025, filed on May 24, 2018.
Prior Publication US 2021/0205280 A1, Jul. 8, 2021
Int. Cl. A61K 31/444 (2006.01); A61K 31/551 (2006.01); A61P 35/02 (2006.01)
CPC A61K 31/444 (2013.01) [A61K 31/551 (2013.01); A61P 35/02 (2018.01)] 5 Claims
 
1. A method of treating inv(16) leukemia in a subject comprising the steps of:
administering to the subject a therapeutically effective combination of:
a) a compound of formula (1a)

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof; and
b) a BRD4 inhibitor selected from JQ1 and a pharmaceutically acceptable salt thereof,
wherein the therapeutically effective combination of the compound of formula (1a) and the BRD4 inhibitor synergistically inhibits proliferation of inv(16) leukemia cells.